Search
ANPDF
Jan 101 min read
Azafaros Community Update | January 9, 2025
Exciting Advances in Azafaros Clinical Programs for NPC and GM Gangliosidoses Azafaros has announced significant progress toward global...
24 views
ANPDF
Dec 20, 20241 min read
Azafaros Community Update | December 20, 2024
Exciting Advances in Azafaros Clinical Programs for NPC and GM Gangliosidoses Today, Azafaros shared an important update about their...
46 views
ANPDF
Jul 17, 20241 min read
Azafaros Media Release | July 16, 2024
Azafaros announces positive topline Phase 2 study data with nizubaglustat in GM2 gangliosidosis and Niemann-Pick disease type C Read the...
27 views
ANPDF
Mar 14, 20241 min read
Azafaros Media Release | March 12, 2024
Azafaros announces completion of 12-week Phase 2 RAINBOW study evaluating lead asset nizubaglustat in rare disease patients.
20 views
ANPDF
Dec 21, 20231 min read
Azafaros Media Release | December 11, 2023
Azafaros’ Phase 2 RAINBOW study, evaluating nizubaglustat in GM2 and NPC patients, is now fully enrolled Read the full statement from...
20 views
ANPDF
Jan 10, 20231 min read
Azafaros Media Releases | January 5-9, 2023
"Azafaros Receives FDA's IND Clearance and Fast Track Designation for Lead Asset AZ-3102" Read the press release from January 5, 2023...
44 views